A potential treatment for patients suffering from Osteoarthritis
Sun Pharmaceutical Industries and Israel-based Moebius Medical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MMII is underway.
The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review.
As we enter Phase 3 development, we are very encouraged by the FDA's decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis, said Marek Honczarenko, MD, PHD, Senior Vice President, Head Global Development at Sun Pharma.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
